搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按相关度排序
按时间排序
15 小时
RBC维持Ideaya Biosciences目标价,看好daro前景
RBC Capital维持Ideaya Biosciences (NASDAQ:IDYA)的"跑赢大市"评级和61.00美元的目标价。该公司的立场是在审查了公司最近关于其药物候选者darolutamide (daro)监管路径的更新后做出的,特别是考虑到积极的二期数据以及FDA对注册试验设计和终点的认可。
1 天
高盛上调Ideaya Biosciences目标价至48美元,基于研究结果
周一,高盛更新了对Ideaya Biosciences (NASDAQ:IDYA)的展望,将目标价从47美元上调至48美元,并维持对该股的买入评级。此次调整是基于该公司宣布的darovasertib (daro)在新辅助治疗葡萄膜黑色素瘤(UM)的2期研究中期结果。 Ideaya Biosciences报告称,49%的患者肿瘤缩小至少30%。此外,在可评估眼球摘除的队列中,61%的患者成功保留了眼 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Would-be assassin charged
Gets 2-yrs for role in fraud
Diagnosed with Parkinson's
Woman dies in 'suicide pod’
Phoenix breaks heat record
Contempt charge coming?
Food packaging cancer risk
Haitian group files complaint
Foreign incentives offer?
‘Trump Train’ jury verdict
Won't call special session
EEOC blocked on rules
To shut down TikTok Music
OR removes 1,200+ voters
PA county ballot ruling
Partners with Google
Calls for US to lift sanctions
Severe obesity on the rise
Helene forms in Caribbean
Dali owner, operator sued
1st NL East title since 2011
Outlaws guitarist dies
NC sending absentee ballots
ISR: Hezbollah leader killed
X account hacked
Recalls 41K+ motorcycles
Rioter mistakenly released
Study about oceans' acidity
Conn. counterfeit drug bust
Executed by lethal injection
反馈